

Art Unit: 1626

DETAILED ACTION

Claims 1-11 are pending in the application. Claims 1-7 and 10 are allowed now renumbered as 1-8. Claims 8, 9 and 11 are cancelled herein by examiner's amendment.

Election/Restrictions

Applicant's election without traverse of the species of example 2 to prosecute the invention of Group I, claims 1-7 and 11 (in part) in the reply filed on December 2nd, 2009 is acknowledged.

Upon entry of the following examiner's amendment, the non-elected subject matter of claims 1-7 and 11 as well as non-elected claims 8 and 9 will be cancelled from the instant claims.

Priority

This application is a 35 U.S.C. 371 National Stage Filing of International Application No. PCT/EP2005/000874, which claims priority under 35 U.S.C. 119(a-d) to U.K. Application No. 0402101.1, filed January 30th, 2004.

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

The information disclosure statement filed July 11th, 2006 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that

Art Unit: 1626

portion which caused it to be listed; and all other information or that portion which caused it to be listed. The examiner has considered the U.S. Patent document cited and lined through the references that have not been provided.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John Alexander on March 3rd, 2010.

The application has been amended as follows:

Claim 1: In line 3, replace "in free or salt form" with "in free or pharmaceutically acceptable salt form".

In lines 14-16, delete the following:

or Y is



where q and r are independently 1 or 2;

In lines 21-23, replace the following:

Art Unit: 1626

n is an integer from 1 to 8 except when Y is



then n is an integer from 2 to 8;

with " n is an integer from 2 to 8;".

Claim 2: In lines 8-10, delete the following:

or Y is



where q and r are both 2;

In lines 13-15, replace the following:

n is an integer from 1 to 8 except when Y is



then n is an integer from 2 to 8; and

with " n is an integer from 2 to 8; and".

Claim 3: In lines 8-10, delete the following:

or Y is



where q and r are both 2;

In lines 14-16, replace the following:

Art Unit: 1626

n is an integer from 1 to 4 except when Y is



then n is an integer from 2 to 4; and

with "n is an integer from 2 to 4; and".

Claim 4: In line 1, replace "of formula I" with "according to claim 1".

In line 3, replace "in free or salt form" with "in free or pharmaceutically acceptable salt form".

In the table, delete the following species:

0	1		
---	---	--	--

Add a period after the table.

Claim 7: In line 1, add the word "an" between "as" and "active".

Claim 8: (cancel)

Claim 9: (cancel)

Claim 10: In line 1, replace "A process for the preparation of compounds of formula I" with "A process for the preparation

Art Unit: 1626

of a compound of formula I in free or pharmaceutically acceptable salt form".

In the last line of the claim, replace "recovering the product in free or salt form" with "recovering the product in free or pharmaceutically acceptable salt form".

Claim 11: (cancel)

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: The closest prior art discovered during the prior art search is U.S. Patent No. 5,274,097 by Schohe et al. which teaches compounds that read on original claim 11. See column 25 and Table 1, entry 1. The prior art fails to teach or suggest the urea group instantly formed by $-Y-C(O)NH-$.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1626

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew P. Coughlin whose telephone number is (571)270-1311. The examiner can normally be reached on Monday through Thursday from 5:30 am - 4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Matthew P. Coughlin/ /Rebecca L Anderson/
Examiner, Art Unit 1626 Primary Examiner, Art Unit 1626